The biology of MDR1-P-glycoprotein (MDR1-Pgp) in designing functional antibody drug conjugates (ADCs): the experience of gemtuzumab ozogamicin

The biology of MDR1-P-glycoprotein (MDR1-Pgp) in designing functional antibody drug conjugates (ADCs): the experience of gemtuzumab ozogamicin

BACKGROUND: The treatment of cancer remains a formidable challenge owing to the difficulties in differentiating tumor cells from healthy cells to ameliorate the disease without causing intolerable toxicity to patients. In addition, the emergence of MDR1-Pgp mediated multi-drug resistance (MDR) it is...

Full description

Bibliographic Details
Main Author:	Maurizio Cianfriglia
Format:	Article
Language:	English
Published:	Istituto Superiore di Sanità 2013-06-01
Series:	Annali dell'Istituto Superiore di Sanità
Subjects:	antibody drug-conjugates gemtuzumab ozogamicin multidrug resistance MDRl-P-glycoprotein AML MDR reversing agent monoclonal antibody
Online Access:	http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S0021-25712013000200008&lng=en&tlng=en

Similar Items

Targeting MDR1-P-glycoprotein (MDR1-Pgp) in immunochemotherapy of acute myeloid leukemia (AML)
by: Maurizio Cianfriglia
Published: (2013-06-01)

Targeted treatment of acute myeloid leukemia in older adults: role of gemtuzumab ozogamicin
by: Hien K Duong, et al.
Published: (2009-05-01)

Gemtuzumab Ozogamicin (Mylotarg) for the Treatment of Acute Myeloid Leukemia – Ongoing Trials
by: Gleissner, Beate, et al.
Published: (2014)

Gemtuzumab ozogamicin and novel antibody-drug conjugates in clinical trials for acute myeloid leukemia
by: Bo Yu, et al.
Published: (2019-10-01)

Gemtuzumab Ozogamicina: uma opção no tratamento de Leucemia mielóide aguda CD33+ Gemtuzumab Ozogamicin: an option in the treatment of acute myeloid leukemia CD33+
by: Celso M. Massumoto, et al.
Published: (2004-12-01)

Therapeutic Targeting of Acute Myeloid Leukemia by Gemtuzumab Ozogamicin
by: Michele Gottardi, et al.
Published: (2021-09-01)

The return of gemtuzumab ozogamicin: a humanized anti-CD33 monoclonal antibody–drug conjugate for the treatment of newly diagnosed acute myeloid leukemia
by: Egan PC, et al.
Published: (2018-11-01)

LYON-UNIVERSITY HOSPITAL EXPERIENCE WITH GEMTUZUMAB OZOGAMICIN THERAPY IN ACUTE MYELOID LEUKEMIA: A ‘REAL-LIFE’ STUDY
by: Xavier Thomas, et al.
Published: (2020-04-01)

Biomarkers of Gemtuzumab Ozogamicin Response for Acute Myeloid Leukemia Treatment
by: Laurène Fenwarth, et al.
Published: (2020-08-01)

Cost-Effectiveness Analysis of Gemtuzumab Ozogamicin for First-Line Treatment of Patients with Cd-33 Positive Acute Myeloid Leukaemia in Spain
by: Mareque M, et al.
Published: (2021-04-01)

Rapid Efficacy of Gemtuzumab Ozogamicin in Refractory AML Patients with Pulmonary and Kidney Failure
by: Daniil Zaytsev, et al.
Published: (2020-02-01)

Gemtuzumab Ozogamicin in the Treatment of Critical Patients with Refractory Acute Myeloid Leukemia (3 Case Reports)
by: DV Zaitsev, et al.
Published: (2019-12-01)

Cost-Effectiveness Analysis of Gemtuzumab Ozogamicin for First-Line Treatment of Patients with Cd-33 Positive Acute Myeloid Leukaemia in Spain [Corrigendum]
by: Mareque M, et al.
Published: (2021-07-01)

Prevention, recognition, and management of adverse events associated with gemtuzumab ozogamicin use in acute myeloid leukemia
by: Jorge E. Cortes, et al.
Published: (2020-10-01)

Clinical and experimental efficacy of gemtuzumab ozogamicin in core binding factor acute myeloid leukemia
by: Michele Gottardi, et al.
Published: (2017-09-01)

Clinical Benefits and Safety of Gemtuzumab Ozogamicin in Treating Acute Myeloid Leukemia in Various Subgroups: An Updated Systematic Review, Meta-Analysis, and Network Meta-Analysis
by: Qingyu Xu, et al.
Published: (2021-08-01)

Case Report: Targeting 2 Antigens as a Promising Strategy in Mixed Phenotype Acute Leukemia: Combination of Blinatumomab With Gemtuzumab Ozogamicin in an Infant With a KMT2A-Rearranged Leukemia
by: Benoît Brethon, et al.
Published: (2021-02-01)

Targeting of CD34<sup>+</sup>CD38<sup>-</sup> cells using Gemtuzumab ozogamicin (Mylotarg) in combination with tipifarnib (Zarnestra) in acute Myeloid Leukaemia
by: Jawad Mays, et al.
Published: (2012-09-01)

A rare case of fatal hepatic veno-occlusive disease and rupture of the spleen vein and artery after Gemtuzumab Ozogamicin (Mylotarg®) infusion Doença veno-oclusiva fatal por Gentuzumab Ozogamicin
by: Celso M. Massumoto, et al.
Published: (2004-01-01)

Inotuzumab ozogamicin in the treatment of relapsed/refractory acute B cell lymphoblastic leukemia
by: Uy N, et al.
Published: (2018-04-01)

Therapeutic Antibodies for Myeloid Neoplasms—Current Developments and Future Directions
by: Christian M. Schürch
Published: (2018-05-01)

CD33 Expression and Gentuzumab Ozogamicin in Acute Myeloid Leukemia: Two Sides of the Same Coin
by: Matteo Molica, et al.
Published: (2021-06-01)

Lysosomal P-gp-MDR1 Confers Drug Resistance of Brentuximab Vedotin and Its Cytotoxic Payload Monomethyl Auristatin E in Tumor Cells
by: Peggy Liu-Kreyche, et al.
Published: (2019-07-01)

Targeted Therapeutic Approach Based on Understanding of Aberrant Molecular Pathways Leading to Leukemic Proliferation in Patients with Acute Myeloid Leukemia
by: Moo-Kon Song, et al.
Published: (2021-05-01)

Inotuzumab ozogamicin: a CD22 mAb–drug conjugate for adult relapsed or refractory B-cell precursor acute lymphoblastic leukemia
by: Yurkiewicz IR, et al.
Published: (2018-07-01)

Assessment of clinical immunogenicity of inotuzumab ozogamicin in patients with non-Hodgkin lymphoma and acute lymphoblastic leukemia
by: Darshana Jani, et al.
Published: (2018-02-01)

Assessment of immunity induced in mice by glycoproteins derived from different strains and species of Leishmania
by: Tânia Mara Pinto Dabés Guimarães, et al.
Published: (1996-02-01)

Multi-drug resistance (MDR1) gene and P-glycoprotein influence on pharmacokinetic and pharmacodymanic of therapeutic drugs
by: Linardi Renata Lehn, et al.
Published: (2006-01-01)

Interactions of the OX-2 lymphoid/neuronal glycoprotein
by: Wright, Gavin James
Published: (1999)

Chk1 Inhibition Restores Inotuzumab Ozogamicin Citotoxicity in CD22-Positive Cells Expressing Mutant p53
by: Elena Tirrò, et al.
Published: (2019-02-01)

Monoclonal antibodies to Ia glycoproteins from rat thymus and spleen
by: McMaster, William Robert
Published: (1979)

The Time Has Come for Targeted Therapies for AML: Lights and Shadows
by: Alessandro Fiorentini, et al.
Published: (2020-01-01)

Determination of P-Glycoprotein Expression by Flow Cytometry in Hematological Malignancies
by: Berkay Saraymen, et al.
Published: (2016-03-01)

Role of MRP-1 and GST-Pi in MDR and their inhibition by indomethacin in AML
by: Samia A. Ebeed, et al.
Published: (2017-08-01)

Identification of intermediate antibodies of broadly neutralizing HIV-1 human monoclonal antibody b12 and characterization of variable loops of HIV-1 envelop glycoprotein
by: Yuan, Tingting, et al.
Published: (2014)

Identification of intermediate antibodies of broadly neutralizing HIV-1 human monoclonal antibody b12 and characterization of variable loops of HIV-1 envelop glycoprotein
by: Yuan, Tingting, et al.
Published: (2014)

Production of horseradish peroxidase conjugated monoclonal anti-heparan sulfate proteoglycans antibody for immunologic assay
by: Nittaya Chansiw, et al.
Published: (2008-09-01)

Renal Ontogeny of P-Glycoprotein/MDR1 in Rat
by: Hodorova I., et al.
Published: (2011-03-01)

Inotuzumab ozogamicin in clinical development for acute lymphoblastic leukemia and non-Hodgkin lymphoma
by: Amandeep Aujla, et al.
Published: (2019-04-01)

Molecular Similarity of MDR Inhibitors
by: Simon Gibbons, et al.
Published: (2004-01-01)